Tirzepatide is the first dual GLP-1/GIP receptor agonist. The dual mechanism produces additive effects on appetite suppression, insulin secretion, glucagon suppression, and adipose tissue insulin sensitivity, explaining the magnitude of weight loss observed.
GLP-1 receptor agonism contributes appetite suppression via central nervous system signaling, delayed gastric emptying, glucose-dependent insulin secretion, and glucagon suppression. GIP receptor agonism adds synergistic insulin secretion, preferential effects on adipose tissue insulin sensitivity, and modest contributions to energy expenditure. SURPASS-2 demonstrated that dual agonism produces approximately 47% more weight loss than single GLP-1 agonism.
This page references peer-reviewed publications listed on PubMed and FDA prescribing information labels. Methodology for source selection is documented on the Methodology page.
Compounded semaglutide + tirzepatide · MD/DO oversight
*12-month plan · flat rate · all titration doses
Or call (949) 818-8000